Bank of New Hampshire Grows Stock Position in Boston Scientific Co. (NYSE:BSX)

Bank of New Hampshire raised its holdings in Boston Scientific Co. (NYSE:BSX) by 14.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,565 shares of the medical equipment provider’s stock after buying an additional 330 shares during the quarter. Bank of New Hampshire’s holdings in Boston Scientific were worth $229,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Private Advisor Group LLC grew its holdings in Boston Scientific by 9.8% in the second quarter. Private Advisor Group LLC now owns 35,059 shares of the medical equipment provider’s stock valued at $2,700,000 after purchasing an additional 3,143 shares during the period. Savant Capital LLC boosted its holdings in shares of Boston Scientific by 2.0% in the 2nd quarter. Savant Capital LLC now owns 14,174 shares of the medical equipment provider’s stock valued at $1,092,000 after purchasing an additional 273 shares during the last quarter. First Foundation Advisors grew its stake in shares of Boston Scientific by 51.2% during the 2nd quarter. First Foundation Advisors now owns 549 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 186 shares during the period. Prudential PLC increased its holdings in shares of Boston Scientific by 6.8% during the 2nd quarter. Prudential PLC now owns 34,685 shares of the medical equipment provider’s stock worth $2,671,000 after buying an additional 2,209 shares during the last quarter. Finally, Wedbush Securities Inc. purchased a new position in shares of Boston Scientific in the 2nd quarter worth $251,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $92.00 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 1 year low of $57.77 and a 1 year high of $92.42. The firm’s 50-day simple moving average is $89.25 and its 200-day simple moving average is $83.50. The firm has a market cap of $135.59 billion, a PE ratio of 76.03, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. Boston Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.50 earnings per share. Equities analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BSX shares. Wells Fargo & Company upped their price target on Boston Scientific from $98.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Morgan Stanley increased their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. BTIG Research lifted their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Evercore ISI increased their price objective on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 27th. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $95.96.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company’s stock, valued at $87,306.06. This represents a 93.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the transaction, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,989 shares of company stock valued at $2,702,261. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.